Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer’s berobenatide through 2028 in exchange for milestone-based payments.
Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer’s berobenatide through 2028 in exchange for milestone-based payments.